高级检索

多肽mPEG-SC20k-HM-3联合奥沙利铂对人肝癌细胞SMMC-7721裸鼠移植瘤的抑制作用

Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice

    摘要
  • 摘要: mPEG-SC20k-HM-3是具有整合素亲和性的一种新型高效血管生成抑制多肽，为探索其与传统化疗药物联用的抗肿瘤活性，建立人肝癌细胞SMMC-7721裸鼠移植瘤模型，选用奥沙利铂为化疗药物，根据临床前抗肿瘤药效学方法评价联合用药的抑瘤作用，并用金氏公式判断两种药物的联合作用。结果显示，与单独用药相比，联合用药组的抑瘤效果更好，且均具有显著差异(P<；0.05)。其中，奥沙利铂(7.5 mg/kg)联合mPEG-SC20k-HM-3(73.4 mg/kg)的肿瘤抑制率为84.6%，抑制作用比单用奥沙利铂(7.5 mg/kg)和单用mPEG-SC20k-HM-3(73.4 mg/kg)均有显著提高。根据金氏公式计算，其Q值为1.164(>；1.15)，可判定该组的用药组合表现出协同作用。结果表明，mPEG-SC20k-HM-3与奥沙利铂单独给药均能抑制肿瘤生长，两者联用对肝细胞癌具有协同作用。

     

    Abstract: mPEG-SC20k-HM-3 is a novel anti-angiogenesis peptide with integrin affinity. To investigate the anti-tumor activities of mPEG-SC20k-HM-3 and oxaliplatin(OXA)combination, a transplanted tumor model of human hepatocellular carcinoma SMMC-7721 in nude mice was established. Jin′s formula to evaluate the combination effect was used. Data suggested that the anti-tumor activities of combined groups were better than those of single drug(P< 0. 05). Inhibition rate of group 8(OXA 7. 5 mg/kg and mPEG-SC20k-HM-3 73. 4 mg/kg)was 84. 6%, which showed remarkable superiority to group 3(OXA 7. 5 mg/kg)and group 4(mPEG-SC20k-HM-3 73. 4 mg/kg). The Q of group 8 was 1. 164(> 1. 15). This combination had synergistic effect. Combination of mPEG-SC20k-HM-3 and oxaliplatin is a method of inhibiting hepatocellular carcinoma.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回

访问量：